89bio Stock Income Statements

89bio Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

89bio Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-01-18	2019-01-18

operating expenses:
research and development	103,902,000	64,394,000	111,303,000	141,441,000	44,865,000	47,428,000	33,592,000	31,417,000	34,915,000	22,306,000	19,064,000	22,197,000	19,686,000	19,849,000	20,979,000	23,590,000	15,630,000	8,770,000	11,208,000	8,443,000	7,778,000	9,989,000	9,989,000
general and administrative	11,922,000	11,515,000	10,702,000	10,497,000	8,571,000	9,849,000	7,614,000	7,928,000	7,214,000	6,218,000	6,298,000	4,844,000	5,052,000	5,259,000	5,262,000	4,622,000	4,921,000	3,777,000	3,225,000	3,230,000	2,924,000	765,000	765,000
total operating expenses	115,824,000	75,909,000	122,005,000	151,938,000	53,436,000	57,277,000	41,206,000	39,345,000	42,129,000	28,524,000	25,362,000	27,041,000	24,738,000	25,108,000	26,241,000	28,212,000	20,551,000	12,547,000	14,433,000	11,673,000	10,702,000	10,754,000	10,754,000
income from operations	-115,824,000	-75,909,000	-122,005,000	-151,938,000	-53,436,000	-57,277,000	-41,206,000	-39,345,000	-42,129,000	-28,524,000	-25,362,000	-27,041,000	-24,738,000	-25,108,000	-26,241,000	-28,212,000	-20,551,000	-86,163,000	14,433,000	11,673,000	10,702,000	10,754,000	10,754,000
yoy	116.75%	32.53%	196.09%	286.17%	26.84%	100.80%	62.47%	45.50%	70.30%	13.61%	-3.35%	-4.15%	20.37%	-70.86%	-281.81%	-341.69%	-292.03%	-901.22%	34.21%
qoq	52.58%	-37.78%	-19.70%	184.34%	-6.71%	39.00%	4.73%	-6.61%	47.70%	12.47%	-6.21%	9.31%	-1.47%	-4.32%	-6.99%	37.28%	-76.15%	-696.99%	23.64%	9.07%	-0.48%
operating margin %
interest expense	-1,137,000	-1,267,000	-1,191,000	-2,362,000	-874,000	-863,000	-866,000	-959,000	-894,000	-2,075,000
interest income and other	6,210,000	6,038,000	5,099,000	5,431,000	6,473,000	6,556,000	5,704,000	5,579,000	4,630,000	1,763,000												0.00%	0.00%
net income before income tax	-110,751,000	-71,138,000	-118,097,000	-148,869,000	-47,837,000	-51,584,000	-36,368,000	-34,725,000	-38,393,000	-28,836,000
income tax expense	-753,000	-137,000	-257,000	-204,000	-134,000	-97,000					-750	-2,000		-1,000				5,750	24,000
net income	-111,504,000	-71,275,000	-118,354,000	-149,073,000	-47,971,000	-51,681,000	-40,235,000	-34,725,000	-38,393,000	-28,836,000	-24,602,000	-26,805,000	-25,054,000	-25,565,000	-26,288,000	-28,329,000	-20,723,000	-86,417,000	14,603,000
yoy	132.44%	37.91%	194.16%	329.30%	24.95%	79.22%	63.54%	29.55%	53.24%	12.79%	-6.41%	-5.38%	20.90%	-70.42%	-280.02%
qoq	56.44%	-39.78%	-20.61%	210.76%	-7.18%	28.45%	15.87%	-9.55%	33.14%	17.21%	-8.22%	6.99%	-2.00%	-2.75%	-7.20%	36.70%	-76.02%	-691.78%
net income margin %
other comprehensive income:
unrealized loss on marketable securities	-244,000	-170,000			-169,000
foreign currency translation adjustments	-19,000	-8,000		-10,000	5,000	5,000	-10,000	6,000	1,000	-4,000	-19,000	14,000	15,000	3,000	6,000	6,000	-6,000	-28,000	10,000
total other comprehensive loss	-263,000	-178,000			-164,000				-354,000									-13,000	3,000
comprehensive loss	-111,767,000	-71,453,000	-119,060,000	-147,121,000	-48,135,000	-52,390,000	-39,498,000	-34,678,000	-38,747,000	-28,726,000	-24,512,000	-26,927,000	-25,116,000	-25,757,000	-26,358,000	-28,327,000	-20,716,000	-86,430,000	14,606,000
net income per share	-0.71	-0.49	-1.05	-1.39	-0.48	-0.54	-0.5	-0.45	-0.52	-0.54	-0.3	-0.57	-1.23	-1.26	-1.3	-1.41	1.03	-0.59	-0.86	0.85	0.76
weighted-average shares used for eps calculation	157,880,203	146,365,115	104,714,613	107,075,197	99,831,111	95,846,740	71,172,870	76,336,050	74,126,569	53,171,370	34,806,349	47,253,527	20,351,560	20,339,416	20,098,340	20,092,094	20,060,061	16,087,785	16,884,244	13,797,356	13,789,786
unrealized gain on marketable securities			-715,000	1,962,000		-714,000
total other comprehensive income			-706,000	1,952,000		-709,000	737,000	47,000		110,000	-94,000	-122,000	-62,000	-192,000	4,000	2,000	7,000
unrealized gain on available-for-sale securities							-50,000	41,000		114,000	-102,000	-136,000	-77,000		-76,000	-4,000	13,000	15,000	-7,000
other comprehensive loss:
unrealized loss on available-for-sale securities									-355,000					-195,000								-29.79	-29.79
other income (expenses)											-133,500	238,000										387,334	387,334
net income before tax											-19,355,250	-26,803,000	-25,054,000	-25,564,000	-15,958,500	-28,329,000	-20,723,000	9,223,750	14,579,000	11,771,000	10,545,000
other incomes													-316,000	-456,000	-194,000	-117,000		-290,000	146,000
other (expenses) income																	-172,000
income tax benefit
other comprehensive (income) loss:
other incomes (income)																				98,000
net income and comprehensive loss																				11,771,000	10,544,000	11,538,000	11,538,000
other income																					-157,000	784,000	784,000
income tax (benefit) expense																					-1,000

We provide you with 20 years income statements for 89bio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 89bio stock. Explore the full financial landscape of 89bio stock with our expertly curated income statements.

The information provided in this report about 89bio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.